Injectable Treatments

BOTOX® COSMETIC & DYSPORT

Botox® Cosmetic and Dysport are used to treat fine lines and wrinkles formed from muscle contraction. These products will not only help diminish lines that already exist, but they will prevent others from forming. The price is calculated per unit. A personalized mapping of the desired area(s) to be treated will determine the number of units needed.

Axillary Hyperhidrosis: Botox Cosmetic is FDA approved for excessive underarm perspiration that is not adequately managed with topical agents. Botox® neurotoxin treatment helps control this condition by temporarily blocking the chemical signals from the nerves that stimulate the sweat glands. When the sweat glands don’t receive chemical signals, the excessive sweating stops. You should notice a significant reduction in underarm sweating within 4 weeks of your first treatment and results should last up to 6-8 months.

DERMAL FILLERS

A variety of dermal fillers are used to fill or replace the lost volume in static wrinkles, lines and folds. Dermal fillers can also be used to enhance, define, or enlarge lips and to shape the face by injection into cheeks, chins, and eyebrows. Temporary fillers offered are: Restylane®, Perlane®, JuvedermTM Ultra, and JuvedermTM Ultra Plus.

Hyaluronidase is a substance that can very quickly reverse temporary hyaluronic acid fillers should there be any misplacement of filler, undesirable effects, or lumps. A topical anesthetic cream is provided and oral blocks are available upon request.

In 2010, the FDA approved JUVÉDERM® XC formulated with the local anesthetic lidocaine to provide patients with a more comfortable injection experience when compared to the non-lidocaine formulation, and potentially less time spent in the physician’s office. JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC contain 0.3% preservative-free lidocaine and numb the treatment area within seconds, potentially reducing the need for an additional anesthetic. JUVÉDERM® XC products provide the same smooth, long-lasting results as demonstrated with existing JUVÉDERM® products.

All dermal fillers, with the exception of Perlane-L, are available in 1/2 cc syringes. 1/2 cc syringes do not contain lidocaine.


BRUISE MD

Trace Skin Care is pleased to offer BruiseMD, a homeopathic remedy – available in topical form and in tablet form – that accelerates the healing of bruises.

The common active ingredient in Bruise MD’s topical forms (Soothing Cream, Cooling Gel and Analgesic Balm) is Arnica Montana, a well-known and well-documented homeopathic remedy. Arnica Montana is a perennial flowering plant and has been used for medicinal purposes for about 500 years.

South American natives have known for thousands of years about the natural enzymatic healing properties of papain in papayas and bromelain in pineapples, and their ability to accelerate wound healing. In BruiseMD Tablets, the therapeutic benefits of papain and bromelain are combined to effectively and efficiently speed up bruise healing.

BruiseMD in all its forms accelerates the rate of bruise healing and reduces the pain, inflammation and discoloration often associated with soft tissue injuries.

Categories


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